Compare Gilead Sciences, Inc. (GILD) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Kimberly Clark Corp — how do they compare? Gilead Sciences, Inc. trades at $132.97 (market cap $163.51B), while Kimberly Clark Corp trades at $108.32 (market cap $35.36B). The key difference: Gilead Sciences, Inc. is far larger — about 4.6× Kimberly Clark Corp's market cap, and Kimberly Clark Corp pays the higher dividend (4.81%). Which is the better fit depends on your goals.
| GILD | KMB | |
|---|---|---|
Market Cap | $163.51B | $35.36B |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $136.77 |
52-Week Low | $108.22 | $93.05 |
Enterprise Value | $178.05B | $41.90B |
Dividend Yield | 2.49% | 4.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Kimberly-Clark (KMB) trades at $106.82, down 3.05% on the day, near the analyst low target of $106.00. The stock shows a bullish technical signal with RSI at 24.78 indicating potential oversold conditions, while recent quarterly EPS beats and a 4.5% dividend yield highlight fundamental strength. The company's pending Kenvue acquisition and innovation-driven growth strategy are key developments, though revenue declined to $16.45B in 2025 from $20.1B in 2024.
KMB offers a stable income play with consistent dividend payments, but investors face risks from high payout ratios and competitive pressures. Analyst consensus is mixed with 32% buy ratings, suggesting cautious optimism. Near-term performance hinges on Q2 2026 earnings due August 4, 2026, with margins under scrutiny amid input cost inflation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
